Literature DB >> 1673992

Effects of inflammatory cytokines and phorbol esters on the adhesion of U937 cells, a human monocyte-like cell line, to endothelial cell monolayers and extracellular matrix proteins.

D E Cavender1, D Edelbaum, L Welkovich.   

Abstract

The accumulation of mononuclear phagocytes at sites of chronic inflammation is dependent on an increase in the rate of extravasation of blood-borne monocytes through the vascular endothelium into the connective tissue. Once the monocytes have emigrated into the connective tissue, they may differentiate into tissue macrophages, presumably following interactions with extracellular matrix proteins. To study these processes, we tested the effects of cytokines and phorbol esters on the adhesion of U937 cells, a human monocyte-like cell line, to cultured endothelial cells (EC) and to matrix proteins. In the absence of cytokines, very few of the U937 cells adhered to EC (5% or less in most experiments). When EC were pretreated for optimal periods of time (4-8 hr) with recombinant interleukin-1 alpha (IL-1 alpha), IL-1 beta, tumor necrosis factor-alpha (TNF alpha), or lymphotoxin (LT; also known as TNF-beta), 35-85% of the U937 cells were able to bind. Interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) did not stimulate U937-EC binding, even though IFN-gamma was shown to increase EC adhesiveness for T lymphocytes. Phorbol esters also greatly stimulated U937-EC adhesion but, in this case, the increase was due to an action on the U937 cells. A monoclonal antibody (MAb), 60.3, against the CD11/CD18 family of leukocyte adhesion molecules partially inhibited the adhesion of untreated and phorbol ester-treated U937 cells to noncytokine-treated EC. However, that MAb had no effect on U937 cell binding to TNF-alpha-treated EC. Thus U937 cells use both CD11/CD18-dependent and -independent mechanisms to adhere to EC. In the absence of stimulating agents, only a small proportion of the U937 cells (2-20%) adhered to fibronectin (FN), and almost none bound to either laminin (LN) or gelatin (denatured type I collagen). In the presence of phorbol esters, a much larger proportion of the U937 cells adhered to FN, with only slight increases in the proportion of cells which bound to LN or gelatin. Additional adhesion assays performed in the presence of a pentapeptide containing the amino acid sequence arg-gly-asp (RGD), which is part of one of the cell-binding domains of FN, demonstrated that the RGD-containing peptide almost totally blocked the phorbol ester-induced adhesion of U937 cells to FN. In contrast, the peptide had no inhibitory effect on the phorbol ester-induced binding of U937 cells to EC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673992     DOI: 10.1002/jlb.49.6.566

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  11 in total

1.  Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases.

Authors:  Clara Lubeseder-Martellato; Eric Guenzi; Anita Jörg; Kristin Töpolt; Elisabeth Naschberger; Elisabeth Kremmer; Christian Zietz; Erwin Tschachler; Peter Hutzler; Martin Schwemmle; Kathrin Matzen; Thomas Grimm; Barbara Ensoli; Michael Stürzl
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines.

Authors:  E Guenzi; K Töpolt; E Cornali; C Lubeseder-Martellato; A Jörg; K Matzen; C Zietz; E Kremmer; F Nappi; M Schwemmle; C Hohenadl; G Barillari; E Tschachler; P Monini; B Ensoli; M Stürzl
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

3.  Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin.

Authors:  H Aung; Z Toossi; J J Wisnieski; R S Wallis; L A Culp; N B Phillips; M Phillips; L E Averill; T M Daniel; J J Ellner
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

4.  Hantaan virus infection of human endothelial cells.

Authors:  M N Pensiero; J B Sharefkin; C W Dieffenbach; J Hay
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes.

Authors:  D A Monshizadegan; D A Holloway; J M Torrente; T Yednock; L Fritz; R J Sturm
Journal:  Agents Actions       Date:  1993

6.  Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis.

Authors:  R N Poston; R R Johnson-Tidey
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

7.  Modulation of monocyte-endothelial cell interactions by platelet microparticles.

Authors:  O P Barry; D Praticò; R C Savani; G A FitzGerald
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

8.  Annexin 1 modulates monocyte-endothelial cell interaction in vitro and cell migration in vivo in the human SCID mouse transplantation model.

Authors:  Mauro Perretti; Francesca Ingegnoli; Samantha K Wheller; Mark C Blades; Egle Solito; Costantino Pitzalis
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

9.  Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells.

Authors:  P Biswas; G Poli; A L Kinter; J S Justement; S K Stanley; W J Maury; P Bressler; J M Orenstein; A S Fauci
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

10.  NRF2 Signaling Negatively Regulates Phorbol-12-Myristate-13-Acetate (PMA)-Induced Differentiation of Human Monocytic U937 Cells into Pro-Inflammatory Macrophages.

Authors:  Min-Gu Song; In-Geun Ryoo; Hye-Young Choi; Bo-Hyun Choi; Sang-Tae Kim; Tae-Hwe Heo; Joo Young Lee; Pil-Hoon Park; Mi-Kyoung Kwak
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.